Premium
Gastrointestinal tract metastasis of lung cancer: The PD‐L1 expression and correlated clinicopathological variables
Author(s) -
Ishikawa Eri,
Nakaguro Masato,
Nakamura Masanao,
Yamamura Takeshi,
Sawada Tsunaki,
Mizutani Yasuyuki,
Maeda Keiko,
Furukawa Kazuhiro,
Shimoyama Yoshie,
Kawashima Hiroki,
Fujishiro Mitsuhiro
Publication year - 2021
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.13048
Subject(s) - medicine , adenocarcinoma , lung cancer , gastrointestinal tract , metastasis , gastrointestinal cancer , colorectal cancer , lung , pathology , immunohistochemistry , cancer , immune system , bowel perforation , oncology , cancer research , immunology , complication
The gastrointestinal tract is a rare site for metastatic lung cancer. Programmed cell death‐ligand 1 (PD‐L1) expression in lung cancer is a biomarker for the response to anti‐PD‐1/PD‐L1 therapy. We investigated clinicopathological features and PD‐L1 expression in 25 gastrointestinal metastatic tumors from the lung and primary adenocarcinoma of the small bowel. The small bowel was the most common site (16/25; 64%) of gastrointestinal tract lung cancer metastasis. A total of 19 (76%) of the gastrointestinal metastasis showed PD‐L1 expression in ≥5% of tumor cells, with 14 (56%) showing high expression levels (≥50%). In contrast, 21 (84%) expressed PD‐L1 in ≥5% immune cells, including 4 (16%) showing a high expression levels (≥50%). The PD‐L1 expression on tumor cells and immune cells in primary lung cancer and corresponding gastrointestinal metastasis was concordant in 13 (68%) and 11 (58%) of the 19 paired cases, respectively. Small‐bowel metastasis of lung cancer was characterized by a higher incidence of perforation (31% vs. 0%), ulcerated mass (83% vs. 60%), and neoplastic PD‐L1 expression (75% vs. 0%) compared to primary small‐bowel adenocarcinoma. Gastrointestinal metastasis from lung cancer might be a potential target for immune checkpoint inhibitor therapy, given its high expression of PD‐L1.